Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K P Johnson

Showing results (141-150 of 148) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 148 results.
Neurology|October 1, 1984
Systemic alpha-interferon therapy of multiple sclerosisR L Knobler, H S Panitch, S L Braheny, et al.
Annals of the New York Academy of Sciences|January 1, 1984
Clinical trial of natural alpha interferon in multiple sclerosisR L Knobler, H S Panitch, S L Braheny, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
Neurology|March 21, 2002
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995K P Johnson, B R Brooks, J A Cohen, et al.
Neurology|April 1, 1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Neurology|March 21, 2002
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]K P Johnson, B R Brooks, J A Cohen, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|January 12, 2002
Novel antineoplastic isochalcones inhibit the expression of cyclooxygenase 1,2 and EGF in human prostate cancer cell line LNCaPK P Johnson, G C Rowe, B A Jackson, et al.
Pageof 15

Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
Neurology|October 1, 1984
Systemic alpha-interferon therapy of multiple sclerosisR L Knobler, H S Panitch, S L Braheny, et al.
Annals of the New York Academy of Sciences|January 1, 1984
Clinical trial of natural alpha interferon in multiple sclerosisR L Knobler, H S Panitch, S L Braheny, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
Neurology|March 21, 2002
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995K P Johnson, B R Brooks, J A Cohen, et al.
Neurology|April 1, 1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Neurology|March 21, 2002
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]K P Johnson, B R Brooks, J A Cohen, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|January 12, 2002
Novel antineoplastic isochalcones inhibit the expression of cyclooxygenase 1,2 and EGF in human prostate cancer cell line LNCaPK P Johnson, G C Rowe, B A Jackson, et al.
Pageof 15